Literature DB >> 23229615

In vitro susceptibility of environmental isolates of Exophiala dermatitidis to five antifungal drugs.

Ana Paula Miranda Duarte1, Fernando Carlos Pagnocca, Noemi Carla Baron, Marcia de Souza Carvalho Melhem, Gislene Aparecida Palmeira, Dejanira de Franceschi de Angelis, Derlene Attili-Angelis.   

Abstract

Several dematiaceous fungi frequently isolated from nature are involved in cases of superficial lesions to lethal cerebral infections. Antifungal susceptibility data on environmental and clinical isolates are still sparse despite the advances in testing methods. The objective of this study was to examine the activities of 5-flucytosine, amphotericin B, itraconazole, voriconazole and terbinafine against environmental isolates of Exophiala strains by minimum inhibition concentration (MIC) determination. The strains were obtained from hydrocarbon-contaminated soil, ant cuticle and fungal pellets from the infrabuccal pocket of attine gynes. Broth microdilution assay using M38-A2 reference methodology for the five antifungal drugs and DNA sequencing for fungal identification were applied. Terbinafine was the most active drug against the tested strains. It was observed that amphotericin B was less effective, notably against Exophiala spinifera, also studied. High MICs of 5-flucytosine against Exophiala dermatitidis occurred. This finding highlights the relevance of studies on the antifungal resistance of these potential opportunistic species. Our results also contribute to a future improvement of the standard methods to access the drug efficacy currently applied to black fungi.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23229615     DOI: 10.1007/s11046-012-9597-9

Source DB:  PubMed          Journal:  Mycopathologia        ISSN: 0301-486X            Impact factor:   2.574


  40 in total

1.  Treatment of chromoblastomycosis.

Authors:  R Pradinaud; T Bolzinger
Journal:  J Am Acad Dermatol       Date:  1991-11       Impact factor: 11.527

2.  In vitro evaluation of the type of interaction obtained by the combination of terbinafine and itraconazole, voriconazole, or amphotericin B against dematiaceous molds.

Authors:  Fernanda Simas Corrêa Biancalana; Luzia Lyra; Angélica Zaninelli Schreiber
Journal:  Antimicrob Agents Chemother       Date:  2011-06-20       Impact factor: 5.191

3.  In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi.

Authors:  A Espinel-Ingroff
Journal:  J Clin Microbiol       Date:  2001-03       Impact factor: 5.948

Review 4.  Pathogenicity of strains of the black yeast Exophiala (Wangiella) dermatitidis: an evaluation based on polymerase chain reaction.

Authors:  J M Uijthof; G S de Hoog; A W de Cock; K Takeo; K Nishimura
Journal:  Mycoses       Date:  1994 Jul-Aug       Impact factor: 4.377

Review 5.  Phaeohyphomycosis.

Authors:  Sanjay G Revankar
Journal:  Infect Dis Clin North Am       Date:  2006-09       Impact factor: 5.982

Review 6.  Dematiaceous fungi.

Authors:  Sanjay G Revankar
Journal:  Mycoses       Date:  2007-03       Impact factor: 4.377

7.  Antifungal activity of antifungal drugs, as well as drug combinations against Exophiala dermatitidis.

Authors:  Yi Sun; Wei Liu; Zhe Wan; Xiaohong Wang; Ruoyu Li
Journal:  Mycopathologia       Date:  2010-08-29       Impact factor: 2.574

8.  Spectrum of clinically relevant Exophiala species in the United States.

Authors:  J S Zeng; D A Sutton; A W Fothergill; M G Rinaldi; M J Harrak; G S de Hoog
Journal:  J Clin Microbiol       Date:  2007-06-27       Impact factor: 5.948

9.  Phaeohyphomycosis in El Salvador caused by Exophiala spinifera.

Authors:  A A Padhye; L Ajello; F W Chandler; J E Banos; E Hernandez-Perez; J Llerena; L M Linares
Journal:  Am J Trop Med Hyg       Date:  1983-07       Impact factor: 2.345

10.  Molecular diversity, new species and antifungal susceptibilities in the Exophiala spinifera clade.

Authors:  R G Vitale; G S de Hoog
Journal:  Med Mycol       Date:  2002-12       Impact factor: 4.076

View more
  6 in total

1.  The bright future of darkness--the rising power of black fungi: black yeasts, microcolonial fungi, and their relatives.

Authors:  G Sybren de Hoog; Vania A Vicente; Anna A Gorbushina
Journal:  Mycopathologia       Date:  2013-05-29       Impact factor: 2.574

2.  Black yeast diversity on creosoted railway sleepers changes with ambient climatic conditions.

Authors:  Ramazan Gümral; Ayşegül Tümgör; Mehmet Ali Saraçlı; Şinasi Taner Yıldıran; Macit Ilkit; G Sybren de Hoog
Journal:  Microb Ecol       Date:  2014-07-16       Impact factor: 4.552

3.  Yeasts in the nests of the leaf-cutter ant Acromyrmex balzani in a Savanna biome: exploitation of community and metabolic diversity.

Authors:  Weilan Gomes da Paixão Melo; Tássio Brito de Oliveira; Silvio Lovato Arcuri; Paula Benevides de Morais; Fernando Carlos Pagnocca
Journal:  Antonie Van Leeuwenhoek       Date:  2021-03-18       Impact factor: 2.271

4.  Combination of Amphotericin B and Terbinafine against Melanized Fungi Associated with Chromoblastomycosis.

Authors:  S Deng; W Lei; G S de Hoog; L Yang; R G Vitale; H Rafati; M Seyedmousavi; A Tolooe; H van der Lee; W Liao; P E Verweij; S Seyedmousavi
Journal:  Antimicrob Agents Chemother       Date:  2018-05-25       Impact factor: 5.191

5.  Antifungal susceptibility and phenotypic characterization of oral isolates of a black fungus from a nasopharyngeal carcinoma patient under radiotherapy.

Authors:  Chaminda Jayampath Seneviratne; Phoenix H L Fong; Sarah S W Wong; Victor H F Lee
Journal:  BMC Oral Health       Date:  2015-03-20       Impact factor: 2.757

6.  A case of Exophiala dermatitidis infection in a child after allogeneic stem cell transplantation: case report and literature review of paediatric cases.

Authors:  Dominika Tanuskova; Julia Horakova; Darina Buzassyova; Miroslava Poczova; Ivana Bodova; Peter Svec; Alica Chocholova; Jaroslava Adamcakova; Tomas Sykora; Miroslava Pozdechova; Lucia Geczova; Alexandra Kolenova
Journal:  JMM Case Rep       Date:  2017-06-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.